Meeting
2024 ASCO Genitourinary Cancers Symposium
Toxicity-benefit analysis of advanced prostate cancer trials using weighted toxicity scoring.
Authors
Jaspreet Kaur Gill
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Jaspreet Kaur Gill , Rubens Copia Sperandio , Tuan Hoang Nguyen , Urban Emmenegger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 110)
DOI
10.1200/JCO.2024.42.4_suppl.110
Abstract #
110
Poster Bd #
E3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Carboplatin in metastatic castrate resistant prostate cancer: A retrospective study of heavily pretreated patients (COMPACT).
First Author: Lara Pemberton
Poster
2023 ASCO Annual Meeting
Effect on outcomes of toxicity-related dose reduction in TKI monotherapy or TKI-IO combination therapy for advanced renal cell carcinoma.
First Author: Giacomo Nuvola
Poster
2022 ASCO Quality Care Symposium
Evaluating the time toxicity of cancer treatment in the CCTG CO.17 randomized clinical trial (RCT).
First Author: Arjun Gupta
Poster
2018 ASCO Annual Meeting
Gemcitabine re-challenge in metastatic soft tissue sarcoma: A therapeutic option for selected patients.
First Author: Ana Sebio